Bilpatide clinical trials
Also written RAY1225.
How each study uses Bilpatide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Bilpatide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- RAY1225
- 11
Studies by the year they started
11 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test Bilpatide, phase 3 first.
- Dec 2026A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AlonePhase 3 · Guangdong Raynovent Biotech Co., Ltd
- Dec 2026A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 DiabetesPhase 3 · Guangdong Raynovent Biotech Co., Ltd
- Nov 2026Evaluation of the Bioequivalence of RAY1225 Injection in Healthy ParticipantsPhase 1 · Guangdong Raynovent Biotech Co., Ltd
Studies
Open first, then newest update. How each study uses Bilpatide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Evaluation of the Bioequivalence of RAY1225 Injection in Healthy ParticipantsNot yet recruitingPhase 1Guangdong Raynovent Biotech Co., LtdNCT07827027Written as RAY1225
- A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AloneNot yet recruitingPhase 3Guangdong Raynovent Biotech Co., LtdNCT07139535Written as RAY1225
- A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 DiabetesNot yet recruitingPhase 3Guangdong Raynovent Biotech Co., LtdNCT07139548Written as RAY1225
- Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are OverweightRecruitingPhase 3Guangdong Raynovent Biotech Co., LtdNCT06893016Written as RAY1225
- A Study of RAY1225 in Participants With Impaired Liver FunctionRecruitingPhase 1Guangdong Raynovent Biotech Co., LtdNCT06577415Written as RAY1225
- A Study of RAY1225 in Participants With ObesityRecruitingPhase 2Guangdong Raynovent Biotech Co., LtdNCT06254261Written as RAY1225
- A Study of RAY1225 in Participants With Type 2 DiabetesCompletedPhase 2Guangdong Raynovent Biotech Co., LtdNCT06254274Written as RAY1225
- The Safety, Tolerability and Pharmacokinetic Study of RAY1225CompletedPhase 1Guangdong Raynovent Biotech Co., LtdNCT05835752Written as RAY1225
- Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and DigoxinActive, not recruitingPhase 1Guangdong Raynovent Biotech Co., LtdNCT07362030Written as RAY1225
- A Study of RAY1225 at Different Injection Sites in Participants With Different Body SizesCompletedPhase 1Guangdong Raynovent Biotech Co., LtdNCT06577428Written as RAY1225
- A Study of RAY1225 in Participants With Impaired Kidney FunctionCompletedPhase 1Guangdong Raynovent Biotech Co., LtdNCT06613763Written as RAY1225